WO1996019232A1 - Combinaisons d'hydrochlorure de ranitidine de forme 1 et de composes du bismuth - Google Patents

Combinaisons d'hydrochlorure de ranitidine de forme 1 et de composes du bismuth Download PDF

Info

Publication number
WO1996019232A1
WO1996019232A1 PCT/IE1995/000015 IE9500015W WO9619232A1 WO 1996019232 A1 WO1996019232 A1 WO 1996019232A1 IE 9500015 W IE9500015 W IE 9500015W WO 9619232 A1 WO9619232 A1 WO 9619232A1
Authority
WO
WIPO (PCT)
Prior art keywords
bismuth
antibiotics
combination product
ranitidine hydrochloride
antibiotic
Prior art date
Application number
PCT/IE1995/000015
Other languages
English (en)
Inventor
Helmut Schickaneder
Aggelos Nikolopoulos
Original Assignee
Lauteral Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lauteral Limited filed Critical Lauteral Limited
Priority to AU16712/95A priority Critical patent/AU1671295A/en
Publication of WO1996019232A1 publication Critical patent/WO1996019232A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Produits obtenus par combinaison d'hydrochlorure de ranitidine de forme 1 et de composés du bismuth pour le traitement d'affections gastro-intestinales. Les produits peuvent également être utilisés en association avec des antibiotiques tels que le nitazoxanide.
PCT/IE1995/000015 1994-12-19 1995-02-03 Combinaisons d'hydrochlorure de ranitidine de forme 1 et de composes du bismuth WO1996019232A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16712/95A AU1671295A (en) 1994-12-19 1995-02-03 Combinations of ranitidine hydrochloride-form 1 and bismuth compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE940972 1994-12-19
IE940972 1994-12-19

Publications (1)

Publication Number Publication Date
WO1996019232A1 true WO1996019232A1 (fr) 1996-06-27

Family

ID=11040596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE1995/000015 WO1996019232A1 (fr) 1994-12-19 1995-02-03 Combinaisons d'hydrochlorure de ranitidine de forme 1 et de composes du bismuth

Country Status (2)

Country Link
AU (1) AU1671295A (fr)
WO (1) WO1996019232A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282132A2 (fr) * 1987-03-09 1988-09-14 The Procter & Gamble Company Compositions et leur utilisation dans le traitement d'affections gastrointestinales
FR2634122A1 (fr) * 1988-07-18 1990-01-19 Glaxo Group Ltd Derives de furanne et leur procede de preparation
EP0626381A1 (fr) * 1993-04-01 1994-11-30 TORCAN CHEMICAL Ltd Préparation de la forme 1 d'hydrochlorure de ranitidine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282132A2 (fr) * 1987-03-09 1988-09-14 The Procter & Gamble Company Compositions et leur utilisation dans le traitement d'affections gastrointestinales
FR2634122A1 (fr) * 1988-07-18 1990-01-19 Glaxo Group Ltd Derives de furanne et leur procede de preparation
EP0626381A1 (fr) * 1993-04-01 1994-11-30 TORCAN CHEMICAL Ltd Préparation de la forme 1 d'hydrochlorure de ranitidine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AL-ASSI M T ET AL: "Clarithromycin, tetracycline, and bismuth: A new nonmetronidazole therapy for Helicobacter pylori infection", AMERICAN JOURNAL OF GASTROENTEROLOGY, 89 (8). 1994. 1203-1205. *
FEDOTIN M.S.: "Helicobacter pylori-associated ulcer disease: Current treatment options", HOSP. FORMUL., 1993, 28/7 (632-634+636+639-640), USA *
GRAHAM D Y ET AL: "EFFECT OF TREATMENT OF HELICOBACTER-PYLORI INFECTION ON THE LONG-TERM RECURRENCE OF GASTRIC OR DUODENAL ULCER A RANDOMIZED CONTROLLED STUDY", ANN INTERN MED, 116 (9). 1992. 705-708. *
GRAHAM D Y ET AL: "SHORT REPORT A NON-METRONIDAZOLE TRIPLE THERAPY FOR ERADICATION OF HELICOBACTER-PYLORI INFECTION TETRACYCLINE AMOXICILLIN BISMUTH", ALIMENT PHARMACOL THER, 7 (1). 1993. 111-113. *
GRAHAM D Y ET AL: "Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 28 (11). 1993. 939-942. *
LABENZ J ET AL: "AMOXICILLIN PLUS OMEPRAZOLE VERSUS TRIPLE THERAPY FOR ERADICATION OF HELICOBACTER-PYLORI IN DUODENAL ULCER DISEASE A PROSPECTIVE RANDOMIZED AND CONTROLLED STUDY", GUT, 34 (9). 1993. 1167-1170. *
LABENZ J ET AL: "Orale Tripeltherapie zur Helicobacter-pylori-Eradikation bei duodenaler Ulkuskrankheit.", MED KLIN, MAY 15 1993, 88 (5) P297-9, GERMANY *

Also Published As

Publication number Publication date
AU1671295A (en) 1996-07-10

Similar Documents

Publication Publication Date Title
CA1147651A (fr) Composes pharmaceutiques a liberation continue
RU2349306C2 (ru) Лекарственные средства, содержащие тригидрат гидрохлорида варденафила
EP0841904A1 (fr) Composition pharmaceutique administrable par voie orale a liberation differee d'un ingredient actif d'inhibiteurs reversibles de la pompe a protons
RU2116071C1 (ru) Лекарственные препараты, набор и способ лечения желудочно-кишечных заболеваний, вызываемых или опосредуемых заражением helicobaeter pylori
EP1142573B1 (fr) COMPOSITIONS pharmaceutiques comprenant du faropenem sodium et un diamine acétate pour améliorer l'absorption gastrointestinale
US5264222A (en) Oral pharmaceutical compositions in unit dosage form
US5128140A (en) Swallowable pharmaceutical compositions
IE920097A1 (en) Swallowable pharmaceutical compositions containing colloidal¹bismuth subcitrate
CA2089748C (fr) Compositions pharmaceutiques contenant du 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]benzimidazole et un agent anti-helicobacter pour le traitement des troublesgastro-intestinaux
RU98104701A (ru) Соли висмута антибиотиков группы моеномицина, способ их получения, их применение и содержащие такие соли лекарственные средства
WO1996019232A1 (fr) Combinaisons d'hydrochlorure de ranitidine de forme 1 et de composes du bismuth
WO1996019220A1 (fr) Produit composite comprenant de la nitazoxanide et un agent antiulcereux
IE950953A1 (en) Pharmaceutical composition.
IE950090A1 (en) Pharmaceutical composition
JPH11508566A (ja) リファブチンを含む抗細菌相乗性組成物
IE862599L (en) Antiinflammatory compositions
US5707653A (en) Ulcer treating composition comprising sufalcrate and antibiotic
EP0664709A1 (fr) Composition pharmaceutique contenant un agent antimicrobien et un antibiotique
CA2169735A1 (fr) Compositions orales d'antagonistes de h2
EP1121124A1 (fr) Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine
IE43165B1 (en) Antidepressant composition
JP3148263B2 (ja) 抗菌性組成物
IE950954A1 (en) A combination product.
EP2343067A1 (fr) Composition pharmaceutique pour l'éradication de l'helicobacter pylori et son procédé de préparation
US9700514B1 (en) Single solid oral dosage forms for treating Helicobacter pylori infection and duodenal ulcer disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DE DK DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA